News | January 26, 2022
Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
